Neuren Pharmaceuticals welcomes milestone approval for Daybu
Neuren Pharmaceuticals has received positive news for the proposed marketing of the Daybu treatment of Rett syndrome.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
